Most recent acquisition makes managing director the company’s second-largest shareholder after founder Cathal Friel
Poolbeg Pharma
Company signs strategic collaboration agreement with a Nasdaq listed biopharma company
It is expected that granting of the application will follow upon completion of formalities.
Biopharmaceutical company hails work with CytoReason as ‘significant breakthrough’
Company recently reported positive data from POLB 001 human challenge trial
Treatment is strain agnostic, and is being developed to treat acute inflammatory conditions
No further clinical activity required, bringing the recruitment and clinical phase to a close on schedule
Company has been working with OneThree Biotech to us artificial intelligence to identify novel drug targets for RSV treatment
US likely to allow Poolbeg application to expand intellectual property protection for influenza drug
Open Orphan spinout has applied for extra intellectual property protection for uses against other illnesses
Largest individual investor understood to be an experienced life science investor
Project could yield new and better treatments for disease
Immunotherapy could be used to treat conditions such as influenza and Covid-19
Company signs licence for MelioVac, a pre-clinical vaccine for melioidosis
Seen & heard: global tax rate above 15%; phasing out leasing of social housing; Poolbeg to seek Nasdaq listing
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices